| INA Pharmaceutics Inc |
74157001390 |
Gabarone™ (Gabapentin) 100MG, 90 ct tabs |
2025-01-22 |
1500.0000 |
None |
1 |
2000 |
None |
None |
None |
None |
None |
None |
None |
None |
| INA Pharmaceutics Inc |
74157011190 |
Gabarone™ (Gabapentin) 400MG, 90 ct tabs |
2025-01-22 |
1500.0000 |
None |
1 |
2000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Incyte Corporation |
50881002311 |
Niktimvo (axatilimab-csfr) injection 22mg/0.44mL, for intravenous use, 1 vial |
2025-01-29 |
11550.0000 |
To market Niktimvo, Incyte designed activities to increase awareness and understanding with healthcare providers about the product. Marketing activities will include education and training provided by our sales force. Consumer-directed communications to educate patients on the disease state and Niktimvo are planned. At Incyte, we are driven by rigorous science and committed to ensuring patients have access to our innovative medicines. We responsibly price our drugs by balancing the value of the outcomes and innovation they bring to patients and the health care system within market and societal expectations. Niktimvo is indicated for 3L treatment of cGVHD. |
None |
3500 |
None |
1 |
2021-09-27 |
152000000.0000 |
None |
Terms of the Collaboration: Under the terms of the agreement, Incyte will lead global commercial activities for axatilimab across all indications. The companies will participate in a 50:50 profit share in the U.S., and Syndax will receive double-digit royalties on sales outside of the U.S. Syndax will retain the option to co-promote axatilimab for any approved indications in the U.S. In connection with the agreement, Syndax will receive an upfront payment of $117 million plus a $35 million equity investment, which will be purchased at $24.62 per share, a 30% premium to the volume weighted average price over the 10 days prior to September 24, 2021. Syndax will also be eligible to receive up to an additional $450 million in potential regulatory, development and commercial milestone payments. The companies will share development costs associated with global and U.S.-specific trials for all agreed upon trials at a rate of 55% (Incyte) and 45% (Syndax), with Incyte responsible for 100% of future development costs for trials that are specific to ex-U.S. countries. Syndax will fund the initial development of axatilimab in IPF and Incyte will have the option to co-fund late-stage development for this indication. |
None |
None |
| Incyte Corporation |
50881003412 |
Niktimvo (axatilimab-csfr) injection 9mg/0.18mL, for intravenous use, 1 Vial |
2025-01-29 |
4725.0000 |
To market Niktimvo, Incyte designed activities to increase awareness and understanding with healthcare providers about the product. Marketing activities will include education and training provided by our sales force. Consumer-directed communications to educate patients on the disease state and Niktimvo are planned. At Incyte, we are driven by rigorous science and committed to ensuring patients have access to our innovative medicines. We responsibly price our drugs by balancing the value of the outcomes and innovation they bring to patients and the health care system within market and societal expectations. Niktimvo is indicated for 3L treatment of cGVHD. |
None |
3500 |
None |
1 |
2021-09-27 |
152000000.0000 |
None |
Terms of the Collaboration: Under the terms of the agreement, Incyte will lead global commercial activities for axatilimab across all indications. The companies will participate in a 50:50 profit share in the U.S., and Syndax will receive double-digit royalties on sales outside of the U.S. Syndax will retain the option to co-promote axatilimab for any approved indications in the U.S. In connection with the agreement, Syndax will receive an upfront payment of $117 million plus a $35 million equity investment, which will be purchased at $24.62 per share, a 30% premium to the volume weighted average price over the 10 days prior to September 24, 2021. Syndax will also be eligible to receive up to an additional $450 million in potential regulatory, development and commercial milestone payments. The companies will share development costs associated with global and U.S.-specific trials for all agreed upon trials at a rate of 55% (Incyte) and 45% (Syndax), with Incyte responsible for 100% of future development costs for trials that are specific to ex-U.S. countries. Syndax will fund the initial development of axatilimab in IPF and Incyte will have the option to co-fund late-stage development for this indication. |
None |
None |
| Ingenus Pharmaceuticals, LLC |
50742055205 |
Fentanyl 50mcg/hr Transdermal Patch |
2025-01-06 |
65.0000 |
Ingenus is a generic pharmaceutical manufacturer and does not market to consumers or health care providers. The Fentanyl Transdermal system is sold primarily to wholesalers and then into the retail drug channel so all marketing efforts are at the wholesaler level.
Ingenus reviews several items in its pricing decisions for our products: competitive market and marketing for similar products, manufacturing costs and complexity to produce a high-quality product, and the ability to source a consistent, high-quality supply of the raw materials and components to manufacture the product. |
None |
6982 |
None |
None |
None |
None |
None |
None |
None |
None |
| Ingenus Pharmaceuticals, LLC |
50742055405 |
Fentanyl 75mcg/hr Transdermal Patch |
2025-01-06 |
75.0000 |
ngenus is a generic pharmaceutical manufacturer and does not market to consumers or health care providers. The Fentanyl Transdermal system is sold primarily to wholesalers and then into the retail drug channel so all marketing efforts are at the wholesaler level.
Ingenus reviews several items in its pricing decisions for our products: competitive market and marketing for similar products, manufacturing costs and complexity to produce a high-quality product, and the ability to source a consistent, high-quality supply of the raw materials and components to manufacture the product. |
None |
10473 |
None |
None |
None |
None |
None |
None |
None |
None |
| Ingenus Pharmaceuticals, LLC |
50742055605 |
Fentanyl 100mcg/hr Transdermal Patch |
2025-01-07 |
95.0000 |
ngenus is a generic pharmaceutical manufacturer and does not market to consumers or health care providers. The Fentanyl Transdermal system is sold primarily to wholesalers and then into the retail drug channel so all marketing efforts are at the wholesaler level.
Ingenus reviews several items in its pricing decisions for our products: competitive market and marketing for similar products, manufacturing costs and complexity to produce a high-quality product, and the ability to source a consistent, high-quality supply of the raw materials and components to manufacture the product. |
None |
13895 |
None |
None |
None |
None |
None |
None |
None |
None |
| Ingenus Pharmaceuticals, LLC |
50742055005 |
Fentanyl 25mcg/hr Transdermal Patch |
2025-01-22 |
35.0000 |
Ingenus is a generic pharmaceutical manufacturer and does not market to consumers or healthcare providers. The Fentanyl Transdermal system is sold primarily to wholesalers and then into the retail drug channel, so all marketing efforts are at the wholesaler level.
Ingenus reviews several items in its pricing decisions for our products. To establish a product's pricing, the company assesses the following: costs associated with product development, competitive market and marketing for similar products, manufacturing costs, the complexity of producing a high-quality product, and the ability to source a consistent, high-quality supply of the raw materials and components to manufacture the product. |
None |
3521 |
None |
None |
None |
None |
None |
None |
The WAC pricing entered is the WAC for a course of therapy. The package WAC of the 25mcg/hr. is $35.00 |
None |
| Ingenus Pharmaceuticals, LLC |
50742054905 |
Fentanyl 12mcg/hr. Transdermal Patch |
2025-01-30 |
55.0000 |
Ingenus is a generic pharmaceutical manufacturer and does not market to consumers or healthcare providers. The Fentanyl Transdermal system is sold primarily to wholesalers and then into the retail drug channel, so all marketing efforts are at the wholesaler level.
Ingenus reviews several items in its pricing decisions for our products. To establish the pricing on a product, the company assesses the following: costs associated with product development, competitive market and marketing for similar products, manufacturing costs and complexity to produce a high-quality product, and the ability to source a consistent, high-quality supply of the raw materials and components to manufacture the product. |
None |
675 |
None |
None |
None |
None |
None |
None |
None |
None |
| Ingenus Pharmaceuticals, LLC |
50742055105 |
Fentanyl 37.5mcg/hr Transdermal Patch |
2025-02-05 |
230.0000 |
Ingenus is a generic pharmaceutical manufacturer and does not market to consumers or healthcare providers. The Fentanyl Transdermal system is sold primarily to wholesalers and then into the retail drug channel, so all marketing efforts are at the wholesaler level.
Ingenus reviews several items in its pricing decisions for our products. To establish the pricing on a product, the company assesses the following: costs associated with product development, competitive market and marketing for similar products, manufacturing costs and complexity to produce a high-quality product, and the ability to source a consistent, high-quality supply of the raw materials and components to manufacture the product. |
None |
542 |
None |
None |
None |
None |
None |
None |
None |
None |
| Ingenus Pharmaceuticals, LLC |
50742055305 |
Fentanyl Transdermal Patch 62.5mcg/hr. |
2025-02-10 |
350.0000 |
Ingenus is a generic pharmaceutical manufacturer and does not market to consumers or healthcare providers. The Fentanyl Transdermal system is sold primarily to wholesalers and then into the retail drug channel, so all marketing efforts are at the wholesaler level.
Ingenus reviews several items in its pricing decisions for our products. To establish the pricing on a product, the company assesses the following: costs associated with product development, competitive market and marketing for similar products, manufacturing costs and complexity to produce a high-quality product, and the ability to source a consistent, high-quality supply of the raw materials and components to manufacture the product. |
None |
865 |
None |
None |
None |
None |
None |
None |
None |
None |
| Ingenus Pharmaceuticals, LLC |
50742055505 |
Fentanyl Transdermal Patch 87.5mcg/hr. |
2025-02-11 |
465.0000 |
Ingenus is a generic pharmaceutical manufacturer and does not market to consumers or healthcare providers. The Fentanyl Transdermal system is sold primarily to wholesalers and then into the retail drug channel, so all marketing efforts are at the wholesaler level.
Ingenus reviews several items in its pricing decisions for our products. To establish the pricing on a product, the company assesses the following: costs associated with product development, competitive market and marketing for similar products, manufacturing costs and complexity to produce a high-quality product, and the ability to source a consistent, high-quality supply of the raw materials and components to manufacture the product. |
None |
935 |
None |
None |
None |
None |
None |
None |
None |
None |